A randomized phase II trial comparing chemoimmunotherapy with or without bevacizumab in previously untreated patients with chronic lymphocytic leukemia

Bevacizumab is a monoclonal antibody targeting vascular endothelial growth factor (VEGF) with in vitro pro-apoptotic and antiangiogenic effects on chronic lymphocytic leukemia (CLL) cells. As monotherapy in patients with CLL, it has no clinical activity. Here we report the results of an open-label,...

Descripción completa

Detalles Bibliográficos
Autores principales: Kay, Neil E., Strati, Paolo, LaPlant, Betsy R., Leis, Jose F., Nikcevich, Daniel, Call, Timothy G., Pettinger, Adam M., Lesnick, Connie E., Hanson, Curtis A., Shanafelt, Tait D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Priority Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346637/
https://www.ncbi.nlm.nih.gov/pubmed/27861157
http://dx.doi.org/10.18632/oncotarget.13412

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346637/
https://www.ncbi.nlm.nih.gov/pubmed/27861157
http://dx.doi.org/10.18632/oncotarget.13412

Ejemplares similares